Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prime Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prime Medicine's regulatory disclosures and financial reporting.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.